Anacor Pharmaceuticals, Inc. (ANAC) Misses Q2 EPS by 2c

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) reported Q2 EPS of ($0.47), $0.02 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $3.11 million.

For earnings history and earnings-related data on Anacor Pharmaceuticals, Inc. (ANAC) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Bernstein SocGen on Performance Food Group (PFGC): 'Not the quarter we were hoping for, but LT story intact'
• Ideal Power (IPWR) Tops Q2 EPS by 2c